论文部分内容阅读
为了探讨肺癌病人血中ＩＬ－１０的来源，我们对４５例实施了肺癌根治术，１５例开胸后未能切除的肺癌病人，１３例胸部良性肿瘤病人，２０例胸部非肿瘤病人开胸手术前１天，术后第１天，第４天，第８天的血中ＩＬ－１０的水平进行了测定，并对４５例肺癌标本进行了免疫组化检测，结果发现：肺癌病人术前ＩＬ－１０水平较胸部良性肿瘤，胸部非肿瘤病人高；术后第１天施行了肺癌根治术病人，ＩＬ－１０水平下降，术后第４，８天明显下降，未切除的肺癌病人术后第１天稍升高，术后第４，８天恢复到术前水平，胸部良性肿瘤病人，胸部非肿瘤病人术后第１天ＩＬ－１０水平轻度上升、术后第４，８天恢复至术前水平，４５例肺癌标本ＩＬ－１０蛋白表达皆阳性。结论：血中ＩＬ－１０来源于肺癌微环境，并且主要来自于肺癌细胞自分泌产生的ＩＬ－１０，提示：ＩＬ－１０在肺癌免疫逃避中起重要作用
To investigate the source of IL-10 in lung cancer patients, we performed radical resection of lung cancer in 45 patients, lung cancer patients who had not been removed after thoracotomy, 13 patients with benign breast tumors, and 20 patients with chest non-tumor patients undergoing thoracotomy. The level of IL-10 in the blood was determined on the first day, the first day, the fourth day and the eighth day after surgery. Immunohistochemical detection was performed on 45 lung cancer specimens. The results showed that: The level of -10 was higher than that of chest benign tumors and non-tumor non-tumor patients. The patients who underwent radical surgery for lung cancer on the first postoperative day showed a decrease in IL-10 levels and a significant decrease on the 4th and 8th days after surgery. It increased slightly on the 1st day and returned to the preoperative level on the 4th and 8th days after surgery. The level of IL-10 was slightly increased on the first postoperative day in patients with benign breast tumors and non-tumor patients in the chest, and returned to the 4th and 8th postoperative days. At the preoperative level, IL-10 protein expression was positive in 45 lung cancer specimens. Conclusion: IL-10 in blood originates from the lung cancer microenvironment and mainly comes from IL-10 secreted by lung cancer cells, suggesting that IL-10 plays an important role in immune evasion of lung cancer.